Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.31 |
| ▸ | WNT3A | P56704 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6402200 | 0.93 | MRGPRX4 (0.35) | MRGPRX4SIGMAR1CTNNB1WNT3A | |
| SCHEMBL6609776 | 0.90 | MRGPRX4 (0.39) | MRGPRX4SIGMAR1TDP1CTNNB1WNT3A | |
| SCHEMBL6607714 | 0.86 | MRGPRX4 (0.32) | MRGPRX4TDP1 | |
| SCHEMBL6399127 | 0.81 | ADRB3 (0.36) | MRGPRX4SIGMAR1CTNNB1WNT3A | |
| SCHEMBL6606835 | 0.81 | ADRB3 (0.36) | MRGPRX4SIGMAR1CTNNB1WNT3A | |
| SCHEMBL6405750 | 0.78 | HPGD (0.38) | SIGMAR1 | |
| SCHEMBL6405755 | 0.78 | HPGD (0.38) | SIGMAR1 | |
| SCHEMBL6406882 | 0.77 | CTSS (0.34) | MRGPRX4TDP1CTNNB1WNT3A | |
| SCHEMBL6406886 | 0.77 | CTSS (0.34) | MRGPRX4TDP1CTNNB1WNT3A | |
| SCHEMBL6406008 | 0.76 | PPARA (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1289980-B1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2004-11-17 | — | — | EP | disclosed |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | CD22, CD2, NEU3 | MRGPRX4 1739/4885SIGMAR1 809/4885TDP1 3282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.